New Products, Protocols

OptiNose files for $100M IPO; GSK wins three-in-one COPD OK

⇨ Yardley, PA-based OptiNose is joining the growing line for Nasdaq, filing for a $100 million IPO, according to the S-1. The filing came right on the heels of an OK for XHANCE — previously referred to by the development name OPN-375 — for the treatment of nasal polyps.

GSK got some good news today, winning FDA approval of the first three-in-one once-daily therapy for COPD. The move comes after the EMA endorsed the inhaler last week.

⇨ After nearly a decade spent collaborating with Celgene, Acceleron $XLRN says it has gained rights to develop sotatercept for pulmonary arterial hypertension, with plans to launch a Phase II study during the first half of next year.

⇨ The microcap biotech Juniper Pharmaceuticals $JNP is refocusing and reorganizing. The plan is to slash the staff roster by 8% and concentrate on “the core businesses of Crinone progesterone gel and Juniper Pharma Services” at the Boston-based women’s healthcare company.

Nabriva Therapeutics $NBRV is following up on a positive Phase III study for its antibiotic with an $80 million stock offering.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing